BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33534825)

  • 1. Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study.
    Chua W; Law JP; Cardoso VR; Purmah Y; Neculau G; Jawad-Ul-Qamar M; Russell K; Turner A; Tull SP; Nehaj F; Brady P; Kastner P; Ziegler A; Gkoutos GV; Pavlovic D; Ferro CJ; Kirchhof P; Fabritz L
    PLoS Med; 2021 Feb; 18(2):e1003405. PubMed ID: 33534825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
    Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation.
    Staszewsky L; Meessen JMTA; Novelli D; Wienhues-Thelen UH; Disertori M; Maggioni AP; Masson S; Tognoni G; Franzosi MG; Lucci D; Latini R
    BMC Cardiovasc Disord; 2021 Nov; 21(1):553. PubMed ID: 34798808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
    Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
    Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death.
    Brady PF; Chua W; Nehaj F; Connolly DL; Khashaba A; Purmah YJV; Ul-Qamar MJ; Thomas MR; Varma C; Schnabel RB; Zeller T; Fabritz L; Kirchhof PF
    J Am Heart Assoc; 2022 Feb; 11(4):e022833. PubMed ID: 35112889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of N-terminal pro-B-type natriuretic peptide level in screening for atrial fibrillation in primary health care.
    Ghazal F; Theobald H; Rosenqvist M; Al-Khalili F
    PLoS One; 2019; 14(2):e0212974. PubMed ID: 30807614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
    Shelton RJ; Clark AL; Goode K; Rigby AS; Cleland JG
    Eur Heart J; 2006 Oct; 27(19):2353-61. PubMed ID: 16952921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation.
    Svennberg E; Henriksson P; Engdahl J; Hijazi Z; Al-Khalili F; Friberg L; Frykman V
    Heart; 2017 Aug; 103(16):1271-1277. PubMed ID: 28255099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure.
    Schnorbach J; Fröhlich H; Täger T; Corletto A; Katus HA; Frankenstein L
    ESC Heart Fail; 2019 Aug; 6(4):640-648. PubMed ID: 31259484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation.
    Chua W; Purmah Y; Cardoso VR; Gkoutos GV; Tull SP; Neculau G; Thomas MR; Kotecha D; Lip GYH; Kirchhof P; Fabritz L
    Eur Heart J; 2019 Apr; 40(16):1268-1276. PubMed ID: 30615112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint Associations of Obesity and NT-proBNP With the Incidence of Atrial Fibrillation in the ARIC Study.
    Almuwaqqat Z; O'Neal WT; Norby FL; Lutsey PL; Selvin E; Soliman EZ; Chen LY; Alonso A
    J Am Heart Assoc; 2019 Oct; 8(19):e013294. PubMed ID: 31564186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-type natriuretic peptide level after sinus rhythm restoration in patients with persistent atrial fibrillation - clinical significance.
    Wozakowska-Kapłon B; Bartkowiak R; Grabowska U; Janiszewska G
    Kardiol Pol; 2010 Jul; 68(7):781-6. PubMed ID: 20648436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
    Santema BT; Chan MMY; Tromp J; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; Ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA
    Clin Res Cardiol; 2020 Mar; 109(3):331-338. PubMed ID: 31263996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke.
    Kneihsl M; Gattringer T; Bisping E; Scherr D; Raggam R; Mangge H; Enzinger C; Fandler-Höfler S; Eppinger S; Hermetter C; Bucnik B; Poltrum B; Niederkorn K; Fazekas F
    Stroke; 2019 Aug; 50(8):2223-2226. PubMed ID: 31216968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: Association with atrial fibrillation progression phenotypes.
    Büttner P; Schumacher K; Dinov B; Zeynalova S; Sommer P; Bollmann A; Husser D; Hindricks G; Kornej J
    Heart Rhythm; 2018 Aug; 15(8):1132-1137. PubMed ID: 29604419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study.
    Xiao J; Persson AP; Engström G; Johnson LSB
    BMC Cardiovasc Disord; 2021 Mar; 21(1):134. PubMed ID: 33711943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.